This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), safety and tolerability of oral semaglutide in healthy male Japanese and Caucasian subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
Once-daily oral administration as tablets.
Unnamed facility
Tokyo, Japan
Area under the semaglutide plasma concentration-time curve
Time frame: During a dosing interval (0-24 hours) at steady state
Maximum observed semaglutide plasma concentration
Time frame: During a dosing interval (0-24 hours) at steady state
Number of treatment emergent adverse events (TEAEs) recorded
Time frame: From the time of first dosing (Day 1) until completion of the follow-up visit (Days 119-126)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.